TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight the promising potential of Arcellx Inc’s anito-cel program. The upcoming iMMagine-1 oral presentation at EHA is expected to reaffirm anito-cel’s best-in-class profile, which is crucial for maintaining the timeline for a potential BLA filing this year and a subsequent launch in the second half of 2026. The addition of MRD negativity as a co-primary endpoint in the iMMagine-3 study could further accelerate approval for earlier lines of treatment.
Furthermore, the impressive topline data from the iMMagine-1 study, presented at ASH, demonstrated high overall response rates and complete response rates, comparable to previous successful studies. The safety profile of anito-cel is anticipated to be favorable, with a low incidence of severe neurotoxicity, which is a significant consideration for its approval and market potential. These factors, combined with management’s confidence in a priority review, support the Buy rating as the program progresses towards commercialization.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $121.00 price target.